
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported)
June 16, 2010**

Cadence Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-33103
(Commission
File Number)

41-2142317
(IRS Employer
Identification No.)

**12481 High Bluff Drive, Suite 200
San Diego, California 92130**
(Address of principal executive offices, including zip code)

(858) 436-1400
(Registrant's telephone number, including area code)

Not applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 5.07 Submission of Matters to a Vote of Security Holders

On June 16, 2010, Cadence Pharmaceuticals, Inc. (the "Company") held its Annual Meeting of Stockholders in San Diego, California. The Company solicited votes by proxy pursuant to proxy solicitation materials first distributed to its stockholders on or about May 6, 2010. The following is a brief description of the proposals voted on at the meeting, all of which were approved, and the final voting results:

Proposal 1. The election of Michael A. Berman, Todd W. Rich and Theodore R. Schroeder as Class I directors for a three-year term expiring at the 2013 Annual Meeting of Stockholders:

<u>Nominee</u>	<u>For</u>	<u>Withheld</u>
Michael A. Berman	42,653,016	97,188
Todd W. Rich	42,725,562	24,642
Theodore R. Schroeder	42,724,462	25,742

Proposal 2. The approval of the amendment and restatement of the Company's 2006 Equity Incentive Award Plan to preserve the Company's ability to deduct compensation associated with future performance-based awards made under the plan to certain executives:

<u>For</u>	<u>Against</u>	<u>Abstain</u>	<u>Broker Non-Votes</u>
32,544,740	10,197,424	8,040	4,080,027

Proposal 3. The ratification of the audit committee's selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2010:

<u>For</u>	<u>Against</u>	<u>Abstain</u>	<u>Broker Non-Votes</u>
46,804,122	10,355	15,754	—

